Belgian-Dutch immunology company argenx <>ARGX.BR said its drug efgartigimod met the primary endpoint in a late-stage study treating adults with autoimmune myositis, showing significant improvement in disease activity.
The Phase 3 trial demonstrated rapid and sustained benefits over a placebo for two subtypes of the muscle-weakening disease, including one that currently has no approved therapies.
